LIFE - aTyr Pharma Inc Stock Price, Fair Value and News

$3.68-0.08 (-2.13%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LIFE Price Action

Last 7 days

-7.3%

Last 30 days

-16.9%

Last 90 days

9.9%

Trailing 12 Months

82.2%

LIFE RSI Chart

LIFE Valuation

Market Cap

327.0M

Price/Earnings (Trailing)

-5.11

Price/Sales (Trailing)

1.4K

EV/EBITDA

-5

Price/Free Cashflow

-4.73

LIFE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LIFE Fundamentals

LIFE Revenue

Revenue (TTM)

235.0K

LIFE Earnings

Earnings (TTM)

-64.0M

Earnings Growth (Yr)

-1.29%

Earnings Growth (Qtr)

13.6%

LIFE Profitability

EBT Margin

-27243.40%

Return on Equity

-91.71%

Return on Assets

-66.14%

Free Cashflow Yield

-21.16%

LIFE Investor Care

Shares Dilution (1Y)

31.16%

Diluted EPS (TTM)

-0.86

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	323.5K	294.0K	264.5K	235.0K
2023	7.9M	5.4M	2.9M	353.0K
2022	0	0	0	10.4M
2020	2.9M	5.4M	7.9M	10.5M
2019	0	0	0	422.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

CEO	Dr. Sanjay S. Shukla M.D., M.S.
WEBSITE	atyrpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	65

aTyr Pharma Inc Frequently Asked Questions

What is the ticker symbol for aTyr Pharma Inc? What does LIFE stand for in stocks?

LIFE is the stock ticker symbol of aTyr Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of aTyr Pharma Inc (LIFE)?

As of Fri Mar 21 2025, market cap of aTyr Pharma Inc is 327 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIFE stock?

You can check LIFE's fair value in chart for subscribers.

Is aTyr Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether LIFE is over valued or under valued. Whether aTyr Pharma Inc is cheap or expensive depends on the assumptions which impact aTyr Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIFE.

What is aTyr Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 21 2025, LIFE's PE ratio (Price to Earnings) is -5.11 and Price to Sales (PS) ratio is 1.39 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIFE PE ratio will change depending on the future growth rate expectations of investors.